INBX Latest Press Releases

-- September 8, 2026 --

Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study PRNewswire 7:32 AM

-- September 4, 2026 --

Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study PRNewswire 4:01 PM

-- August 13, 2026 --

Inhibrx Reports Second Quarter 2026 Financial Results PRNewswire 4:05 PM

-- July 16, 2026 --

Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million PRNewswire 9:00 AM

-- June 15, 2026 --

Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma PRNewswire 9:15 AM

-- May 14, 2026 --

Inhibrx Reports First Quarter 2026 Financial Results PRNewswire 4:02 PM

-- May 11, 2026 --

Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy PRNewswire 8:00 AM

-- May 8, 2026 --

Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC PRNewswire 4:00 PM

-- April 21, 2026 --

Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer PRNewswire 4:05 PM

-- April 20, 2026 --

Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer PRNewswire 5:04 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software